BSE Healthcare PB	6.5
BSE Healthcare PE	39.4
BSE Healthcare DIV	0.5
BSE Healthcare EPS	1,109.3

BSE Healthcare News and Updates

Keep track of all breaking news on BSE Healthcare from all sources in a single place.

28 Aug 2025, 11:27AM

5168.00

-1.54%

Why getting Covid-19 vaccine is likely to be more complicated this year?

Business Line

The US Food and Drug Administration has OK'd new shots from Pfizer, Moderna and Novavax, but the approvals came with some new caveats

Pfizer Ltd. has gained 27.60% in the last 6 Months

SMS Pharmaceuticals Ltd.

28 Aug 2025, 10:46AM

225.77

-2.44%

SMS Pharmaceuticals shares zoom 10% on clean USFDA inspection report

Business Standard

SMS Pharmaceuticals shares rose 10 per cent after it received an Establishment Inspection Report with a No Action Indicated from the USFDA

Promoters unpledged 5.11% of shares in last quarter. Total pledge stands at 32.49% of promoter holdings

Cipla Ltd.

27 Aug 2025, 07:02PM

1580.30

0.03%

Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US

NDTV Profit

The company is recalling 20,352 packs of the inhalation drug due to 'Failed Stability Specifications

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla recalls over 20k packs of inhalation drug in US

Business Line | 27 Aug 2025, 04:53PM

Sai Life Science Ltd.

26 Aug 2025

816.05

-5.23%

Sai Life Sciences Bulk Deal: TPG Exits Via Rs 2,675-Crore Sale; Societe Generale, Goldman Sachs Acquire

NDTV Profit

IIFL Capital Services Ltd., Kotak Securities Ltd. and Jefferies India Pvt. were the bookrunners for the deal.

Promoters unpledged 2.66% of shares in last quarter. Total pledge stands at 0.01% of promoter holdings

Sai Life Sciences slips 5% on heavy volumes; should you buy, sell or hold?

Business Standard | 26 Aug 2025 1 more

Dr. Reddy's Laboratories Ltd.

26 Aug 2025

1259.80

-0.27%

Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access

Business Standard

Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the cost efficiency of domestic manufacturing and the affordability of medicines, Dr Reddy's Laboratories Chairman Satish Reddy said in a statement. "We are optimistic that the forthcoming reforms will address these critical concerns and introduce a rationalised, industry-friendly tax framework," he noted. Such measures will significantly improve the affordability and accessibility of essential medicines for every citizen, while also enhancing the global competitiveness and innovation capacity of the Indian pharmaceutical industry, Reddy said. The industry remains fully committed to working in close partnership

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr Reddy's launches drug for treatment of chronic constipation

Business Line | 26 Aug 2025 1 more

Aurobindo Pharma Ltd.

26 Aug 2025

1026.30

-1.85%

Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

Business Standard

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment

Aurobindo Pharma Ltd. has lost -33.87% in the last 1 Year

Indoco Remedies Ltd.

26 Aug 2025

274.20

-1.10%

Nirmal Bang Remains Structurally Positive On Indoco Remedies; Maintains 'Hold' Rating Check Target Price

NDTV Profit

Nirmal Bang values the company at 11x Jul-27E EV/Ebitda and maintain Hold rating on Indoco Remedies, resulting in a target price of Rs 310.

Indoco Remedies Ltd. has gained 37.07% in the last 6 Months

Sun Pharmaceutical Industries Ltd.

26 Aug 2025

1585.70

-0.91%

Sun Pharma shares slip 3% after BofA downgrade on premium valuations

Economic Times

Bank of America downgraded Sun Pharma stock to underperform' from neutral', citing risks to premium valuations and slower speciality execution. The brokerage cut its target price, flagging concerns over Ilumya's Medicare exposure, pricing pressures, and limited earnings visibility despite strong initial performance.

Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.

Senores Pharmaceuticals Ltd.

25 Aug 2025

697.95

-1.31%

Broker's call: Senores Pharma (Buy)

Business Line

Choice International

Senores Pharmaceuticals Ltd. has gained 39.14% in the last 3 Months

Akums Drugs & Pharmaceuticals Ltd.

25 Aug 2025

467.90

-1.93%

Akums Drugs announces JV to set up manufacturing facility in Zambia

Business Standard

Akums will hold 51% in its joint venture with the Zambian government to set up a pharma manufacturing facility, marking its first overseas plant and Africa expansion

ICICI Securities Limited decreased Buy price target of Akums Drugs & Pharmaceuticals Ltd. to 655.0 on 11 Aug, 2025.

Is BSE Healthcare worth buying?

20 Votes:

Buy 85.0%

Sell 10.0%

Hold 5.0%

52W high on Jul 30, 2025

BSE Healthcare PB

BSE Healthcare PE

BSE Healthcare DIV

BSE Healthcare EPS

BSE Healthcare News and Updates

Keep track of all breaking news on BSE Healthcare from all sources in a single place.